2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[2-(1,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)-ethoxy]-benzyl}-1H-indol-5-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[2-(1,3,3-trimethyl-6-aza-bicyclo[3.2.1 ]oct-6-yl)-ethoxy]-benzyl}-1H-indol-5-ol
• 英文别名: 2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[2-(1,3,3-trimethyl-6-aza-bicyclo[3.2.1H]oct-6-yl)-ethoxy]-benzyl}-1H-indol-5-ol；2-(4-Hydroxyphenyl)-3-methyl-1-[[4-[2-(1,3,3-trimethyl-6-azabicyclo[3.2.1]octan-6-yl)ethoxy]phenyl]methyl]indol-5-ol
• 化学式: C₃₄H₄₀N₂O₃
• 分子量: 524.703
• InChiKey: XBAAJDINCFRSJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  39
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  57.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Methods of treating breast disorders
  申请人：American Home Products Corporation

  公开号：US20020016318A1

  公开（公告）日：2002-02-07

  This invention comprises methods of treating treatment of breast disorder comprising administration of a compound of the formulae I or II: 1 wherein Z is a moiety selected from the group of: 2 wherein: R 1 is selected from H, OH or the C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, or halogens; or C 1 -C 4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R 2 , R 3 , R 4 , R 5 , and R 6 are H, OH or C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, halogens, or C 1 -C 4 halogenated ethers, cyano, C 1 -C 6 alkyl, or trifluoromethyl, with the proviso that, when R 1 is H, R 2 is not OH; Y is the moiety: 3 R7 and R8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof.

  该发明涉及治疗乳腺疾病的方法，包括给予化合物I或II的治疗：其中Z是从以下组中选择的基团之一：其中：R1选自H、OH或其C1-C12酯或C1-C12烷基醚，或卤素；或C1-C4卤代醚包括三氟甲基醚和三氯甲基醚；R2、R3、R4、R5和R6是H、OH或其C1-C12酯或C1-C12烷基醚，卤素，或C1-C4卤代醚，氰基，C1-C6烷基，或三氟甲基，但当R1为H时，R2不是OH；Y是基团：R7和R8是烷基或连接在一起形成一个可选择取代的含氮环；或其药用盐。
• Combination therapy for inhibiting sphincter incontinence
  申请人：American Home Products Corporation

  公开号：US20020019377A1

  公开（公告）日：2002-02-14

  This invention comprises methods of inducing or maintaining sphincter continence, or inhibiting or alleviating incontinence, in a mammal comprising administration of a compound of the formulae I or II: 1 wherein Z is a moiety selected from the group of: 2 wherein: R 1 is selected from H, OH or the C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, benzyloxy, or halogens; or C 1 -C 4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R 2 , R 3 , R 4 , R 5 , and R 6 are H, OH or C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, halogens, or C 1 -C 4 halogenated ethers, cyano, C 1 -C 6 alkyl, or trifluoromethyl, with the proviso that, when R 1 is H, R 2 is not OH; Y is the moiety: 3 R7 and R8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof.

  这项发明涉及诱导或维持哺乳动物的括约肌控制，或抑制或缓解失禁的方法，包括给予化合物I或II的给药：其中Z是从以下组中选择的基团之一：其中：R1选择自H、OH或其C1-C12酯或C1-C12烷基醚、苄氧基或卤素；或C1-C4卤代醚，包括三氟甲基醚和三氯甲基醚；R2、R3、R4、R5和R6是H、OH或其C1-C12酯或C1-C12烷基醚、卤素、或C1-C4卤代醚、氰基、C1-C6烷基或三氟甲基，但当R1为H时，R2不是OH；Y是基团：R7和R8是烷基或连接在一起形成一个可选择取代的含氮环；或其药用盐。
• Methods of treating prosthesis-related bone degeneration
  申请人：American Home Products Corporation Five Giralda Farms

  公开号：US20020022613A1

  公开（公告）日：2002-02-21

  This invention comprises methods of treating bone prosthesis degeneration comprising administration of a compound of the formulae I or II: 1 wherein Z is a moiety selected from the group of: 2 wherein: R 1 is selected from H, OH or the C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, or halogens; or C 1 -C 4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R 2 , R 3 , R 4 , R 5 , and R 6 are H, OH or C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, halogens, or C 1 -C 4 halogenated ethers, cyano, C 1 -C 6 alkyl, or trifluoromethyl, with the proviso that, when R 1 is H, R 2 is not OH; Y is the moiety: 3 R 7 and R 8 are alkyl or concatentated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof.

  这项发明涉及治疗骨假体退化的方法，包括给予化合物I或II的治疗：其中Z是从以下组中选择的基团：其中：R1选择自H、OH或其C1-C12酯或C1-C12烷基醚，或卤素；或C1-C4卤代醚，包括三氟甲醚和三氯甲醚；R2、R3、R4、R5和R6是H、OH或其C1-C12酯或C1-C12烷基醚，卤素，或C1-C4卤代醚，氰基，C1-C6烷基，或三氟甲基，但当R1为H时，R2不是OH；Y是基团：R7和R8是烷基或连接在一起形成一个可选择取代的含氮环；或其药用盐。
• Combinations of bisphosphonates and estrogenic agents
  申请人：American Home Products Corporation

  公开号：US20020019373A1

  公开（公告）日：2002-02-14

  This invention comprises methods of treating bone disorders comprising administration of a bisphosphonate and compound of the formulae I or II: 1 wherein Z is a moiety selected from the group of: 2 wherein: R 1 is selected from H, OH or the C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, benzyloxy, or halogen; or C 1 -C 4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R 2 , R 3 , R 4 , R 5 , and R 6 are H, OH or C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, halogens, or C 1 -C 4 halogenated ethers, cyano, C 1 -C 6 alkyl, or trifluoromethyl, with the proviso that, when R 1 is H, R 2 is not OH; Y is the moiety: 3 R 7 and R 8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof.

  这项发明涵盖了治疗骨骼疾病的方法，包括给予双磷酸盐和式I或II的化合物：其中Z是从以下组中选择的一个基团：其中：R1选择自H、OH或其C1-C12酯或C1-C12烷基醚、苄氧基或卤素；或C1-C4卤代醚，包括三氟甲基醚和三氯甲基醚；R2、R3、R4、R5和R6是H、OH或其C1-C12酯或C1-C12烷基醚、卤素、或C1-C4卤代醚、氰基、C1-C6烷基或三氟甲基，但是当R1是H时，R2不是OH；Y是基团：R7和R8是烷基或连接在一起形成一个可选择取代的含氮环的；或其药用盐。
• Methods of treating neuropeptide Y-related conditions
  申请人：American Home Products Corporation

  公开号：US20020019392A1

  公开（公告）日：2002-02-14

  This invention comprises methods of treating treatment or prevention of diseases associated with an excess of neuropeptide Y comprising administration of a compound of the formulae I or II: 1 wherein Z is a moiety selected from the group of: 2 wherein: R 1 is selected from H, OH or the C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, benzyloxy, or halogen; or C 1 -C 4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R 2 , R 3 , R 4 , R 5 , and R 6 are H, OH or C 1 -C 12 esters or C 1 -C 12 alkyl ethers thereof, halogens, or C 1 -C 4 halogenated ethers, cyano, C 1 -C 6 alkyl, or trifluoromethyl, with the proviso that, when R 1 is H, R 2 is not OH; Y is the moiety: 3 R 7 and R 8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof.

  这项发明涉及治疗或预防与神经肽Y过量相关的疾病的方法，包括给予式I或II的化合物：其中Z是从以下组中选择的基团之一：其中：R1选择自H、OH或其C1-C12酯或C1-C12烷基醚、苄氧基或卤素；或C1-C4卤代醚，包括三氟甲基醚和三氯甲基醚；R2、R3、R4、R5和R6是H、OH或其C1-C12酯或C1-C12烷基醚、卤素、或C1-C4卤代醚、氰基、C1-C6烷基或三氟甲基，但当R1是H时，R2不是OH；Y是基团：R7和R8是烷基或连接在一起形成一个可选择替代的含氮环的；或其药用盐。